A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma
This multicenter Phase II study is evaluating the safety, antitumor activity, and immunogenicity of MEDI4736 (durvalumab) and tremelimumab given together and individually in patients with unresectable hepatocellular carcinoma. Both drugs are administered intravenously (by vein).
This study is for patients who:
- Have unresectable hepatocellular carcinoma.
- Have not previously received immunotherapy.
- Are age 18 or older.
For more information and to inquire about eligibility for this study, please contact Dr. Ghassan Abou-Alfa at 646-888-4184.